Application of modified citrate anticoagulant regimen to plasma exchange in patients with hepatic failure

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100044654

Enrollment

Unknown

Registered

2021-03-25

Start date

2021-03-25

Completion date

Unknown

Last updated

2021-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatic failure

Interventions

Modified citrate group:Improved citrate anticoagulation technique

Conventional citrate group:Conventional citrate anticoagulant Technology

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Aged > 18 years; (2) Patients with liver failure, and with plasma exchange treatment indications.

Exclusion criteria

Exclusion criteria: (1) Allergic to plasma; (2) Due to circulatory instability and other unexpected interruption of treatment; (3) Patients with lactic acid > 7; (4) Refractory acidosis patients with pH < 7.2.

Design outcomes

Primary

Measure	Time frame
bilirubin;	—

Secondary

Measure	Time frame
Coagulation function;	—

Countries

China

Contacts

Public ContactYang Rongli

Dalian Municipal Central Hospital

yever3000@yeah.net+86 15904963796

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026